Estimation of the familial relative risk of cancer by site from a French population based family study on colorectal cancer (CCREF study)

Andrieu, N.; Launoy, G.; Guillois, R.; Ory-Paolelti, C.; Gignoux, M.
September 2004
Gut;Sep2004, Vol. 53 Issue 9, p1322
Academic Journal
Background: Colorectal cancer (CRC) is the second most common cause of death from cancer in France. A family history of CRC increases an individual's risk of developing CRC. Family history has been suggested to have a greater impact on proximal than distal tumours. AIM: We estimated the familial risk of CRC and other cancers, and examined how risk varies according to localisation of the tumor in the colorectal tract. Subjects: We recorded all cases of CRC diagnosed between 1993 and 1998 in the region served by the Calvados Cancer Registry. A trained interviewer asked all participants about their family history of cancer. Statistical methods: Familial risk was estimated from a cohort analysis of the relatives of the CRC cases. The expected numbers of cancers were calculated from Calvados incidence rates. Familial relative risks were calculated using standardised incidence ratios. Results: Our findings showed that colon cancer had a stronger familial/genetic component (relative risk (RR) 1.47) than rectal cancer (RR 0.98). The familial/genetic component appeared stronger for proximal colon cancer than for distal colon cancer only among women (RR 2.24 v RR 1.45). CRC appeared to be positively associated with leukemia (RR 1.77), stomach cancer (RR 1.32), and testicular cancer (RR 3.13), and negatively associated with urinary bladder cancer (RR 0.57) within families. The cancer spectrum associated with CRC among younger participants included prostate (RR 1.93), uterus (RR 2.49), and thyroid (RR 3.85) cancers. Conclusion: If our results are confirmed, follow up guidelines for patients with a family history of CRC should depend on the sex and tumor site of affected relatives to avoid needless invasive screening.


Related Articles

  • Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry. Ringland, C. L.; Arkenau, H.-T.; O'Connell, D. L.; Ward, R. L. // Annals of Oncology;Jan2010, Vol. 21 Issue 1, p92 

    Background: We examined the rate of second primary colorectal cancer (SPCRC) in a cohort of 29 471 patients first diagnosed with colorectal cancer (CRC) from 1987 to 1996, in New South Wales (NSW), Australia.

  • Proximal Tumors Are Associated with Greater Mortality in Colon Cancer. Wong, Robert // JGIM: Journal of General Internal Medicine;Nov2010, Vol. 25 Issue 11, p1157 

    BACKGROUND: Colon cancer is the third leading cause of death from cancer in the United States. Recent studies report on increasing proportions of proximal cancers. The etiology behind this epidemiological trend is unclear, and its implication on survival outcomes is unknown. Further analysis of...

  • Vegetable and Fruit Consumption and Risks of Colon and Rectal Cancer in a Prospective Cohort Study The Netherlands Cohort Study on Diet and Cancer. Voorrips, L. E.; Goldbohm, R. A.; van Poppel, G.; Sturmans, F.; Hermus, R. J. J.; van den Brandt, P. A. // American Journal of Epidemiology;Dec2000, Vol. 152 Issue 11, p1081 

    The relation between vegetable and fruit consumption and colorectal cancer risk was comprehensively assessed in the Netherlands Cohort Study on Diet and Cancer using a validated 150-item food frequency questionnaire. After 6.3 years of follow-up (1986–1992), over 1,000 incident cases of...

  • Influence of a complementary treatment with oral enzymes on patients with colorectal cancers – an epidemiological retrolective cohort study. Popiela, Tadeusz; Kulig, Jan; Hanisch, Jürgen; Bock, Paul R. // Cancer Chemotherapy & Pharmacology. Supplement;Jun2001, Vol. 47, pS55 

    Purpose: To evaluate the impact of postoperative treatment with an oral enzyme (OE) preparation given complementary to an antineoplastic therapy in patients with all stages of colorectal cancer. Methods: The design of this epidemiological study was a retrolective cohort analysis with parallel...

  • Quality management in rectal carcinoma: what is feasible? Merkel, Susanne; Klossek, Daniela; Göhl, Jonas; Papadopoulos, Thomas; Hohenberger, Werner; Hermanek, Paul // International Journal of Colorectal Disease;Aug2009, Vol. 24 Issue 8, p931 

    A cohort study was carried out to analyse quality indicators in the diagnosis and treatment of rectal carcinoma. A total of 2,470 patients with rectal carcinoma treated between 1985 and 2007 at the Department of Surgery, University of Erlangen, were analysed and compared within four time...

  • Does comorbidity interact with colorectal cancer to increase mortality? A nationwide population-based cohort study. Erichsen, R; Horváth-Puhó, E; H Iversen, L; Lash, T L; Sørensen, H T // British Journal of Cancer;10/1/2013, Vol. 109 Issue 7, p2005 

    Background:It is unknown whether comorbidity interacts with colorectal cancer (CRC) to increase the rate of mortality beyond that explained by the independent effects of CRC and comorbid conditions.Methods:We conducted a cohort study (1995-2010) of all Danish CRC patients (n=56 963), and five...

  • Immunoprofiling for Prognostic Assessment of Colon Cancer: a Novel Complement to Ultrastaging. Lavotshkin, Simon; Jalas, John; Torisu-Itakura, Hitoe; Ozao-Choy, Junko; Lee, Ji; Sim, Myung; Stojadinovic, Alexander; Wainberg, Zev; Bifulco, Carlo; Fox, Bernard; Bilchik, Anton // Journal of Gastrointestinal Surgery;Jun2015, Vol. 19 Issue 6, p999 

    Background: Although AJCC/TNM staging remains the gold standard for prognostic assessment of colon cancer, stage-specific outcomes vary. We therefore prospectively evaluated the prognostic role of immunoprofiling. Methods: Our cohort included 35 patients from an ongoing prospective trial of...

  • Gastrin releasing peptide, receptor associated with improved colon cancer survival.  // Hem/Onc Today;7/10/2009, Vol. 10 Issue 13, p21 

    The article discusses a study presented at the 2009 Digestive Disease Week in Chicago, Illinois which examined tumor resections of patients with stage II colon cancer and with stage III disease.

  • Clinical Review: Colorectal cancer.  // GP: General Practitioner;6/27/2012, p25 

    The article offers information on the clinical symptoms of colorectal cancer (CRC). It mentions CRC is the third most common cancer in the Great Britain following breast cancer and lung cancer. Further it mentions the risk factors include family history and about 95 percent of sporadic CRC...


Read the Article


Sign out of this library

Other Topics